Drug
Dsp 0390
Dsp 0390: highest development phase Phase 1, developed by Sumitomo Pharma. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| DSP-0390 NCT07545954 | Phase 1 | Small-cell Lung Cancer |
| DSP-0390 NCT06636162 | Phase 1 | Glioma, Malignant |
| DSP-0390 NCT05023551 | Phase 1 | High Grade Glioma |
Latest
No recent events.
Follow Dsp 0390 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.